1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Industry in Ghana and Nigeria

Pharmaceutical Industry in Ghana and Nigeria

  • June 2014
  • -
  • Frost & Sullivan
  • -
  • 204 pages

A Ripe Business Opportunity for Big Pharma and Generic Pharma Companies

The pharmaceutical industry in Ghana and Nigeria is forecast to represent a combined business opportunity of over $3 billion by 2018, propelled by a convergence of changing economic profiles, increased healthcare spending and investment, and increasing incidence of chronic diseases. Market segmentation is done based on products (OTC, generic, and branded) as well as therapeutic areas (anti-infectives, cardiovascular, diabetes, oncology, respiratory, and CNS). This study provides a detailed analysis that includes market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the pharmaceutical industry in Ghana and Nigeria.

Methodology

-Primary interviews were conducted with industry stakeholders such as Tier I and Tier II pharmaceutical companies, industry experts, and regulatory authorities. Designation of interviewed participants include chief executive officers, marketing managers, directors, and vice presidents.
-Secondary research sources such as in-house Frost & Sullivan database, Frost & Sullivan’s Decision Support Database, company annual reports, scientific journals, and industry-related articles have been utilised.
-For the purpose of this research, West African pharmaceutical industry refers to the pharmaceutical industry in Ghana and Nigeria.
-Revenues include drug sales from local manufacturers, multinational companies that either establish their own business units or trade via a local distributor as well as imports from generic pharmaceutical companies.
-Over-the-counter (OTC) products have been included in the scope of this study.

Key Findings

-In 2013, the pharmaceutical industry of Ghana and Nigeria was valued at $ billion. It is expected to witness a compound annual growth rate (CAGR) of % and generate a revenue of $ billion in 2018.
-Nigeria accounted for % of the revenue in the total Ghanaian and Nigerian pharmaceutical industry in 2013 because of its large size, while Ghana accounted for the remaining %.
-In 2013, the generic pharmaceutical segment represented the highest revenue share of %, while the branded pharmaceutical segment represented the least.
-The OTC pharmaceutical segment is considerably large in Ghana and Nigeria, constituting % of the total pharmaceutical industry, attributable to the large number of local manufacturers particularly in the anti-infectives, analgesics, and multivitamins product segments.
-In 2013, the anti-infectives therapeutic segment accounted for the highest revenue share of% of the total pharmaceutical industry in Ghana and Nigeria. It is expected to witness a high CAGR from 2013 to 2018 and remain the largest therapeutic segment during the forecast period.
-Although the oncology therapeutic segment accounted for the smallest revenue share in 2013, it is expected to be the fastest growing segment during the forecast period, given the increasing awareness about cancer in Ghana and Nigeria.
-The cardiovascular and diabetes therapeutic segments are also projected to witness high growth rates during the forecast period as a result of increasing adoption of western lifestyle, driving the demand for consumption of chronic drugs.
-The continuous burden of anti-infectives, including malaria, tuberculosis (TB), and HIV/AIDS in West Africa is expected to be the major growth driver for this industry.
-The increased prevalence of non-communicable diseases (NCDs) such as hypertension, diabetes, and cancer in Ghana and Nigeria is expected to have a high impact on the growth of the total pharmaceutical industry as the demand for chronic prescription therapy for these diseases rises.
-The recent achievement of % NHIS coverage in Ghana in 2013 is expected to result in high growth of the pharmaceutical industry, particularly the prescription pharmaceutical (generic and branded) segment, because of easy accessibility and affordability of medicines.
-The judicious efforts of the Food and Drugs Board (FDB) (Ghana) and National Agency for Food (NAFDAC) (Nigeria) to control parallel trading and imports of counterfeit drugs are expected to contribute to the growth of the legitimate pharmaceutical industry in Ghana and Nigeria.
-Furthermore, the governments are also encouraging the local production of essential medicines to improve capacity utilisation and reduce imports.

Table Of Contents

Pharmaceutical Industry in Ghana and Nigeria
1. EXECUTIVE SUMMARY

Key Findings
Scope and Segmentation
Market Segmentation
Key Questions This Study Will Answer
Market Engineering Measurements
CEO's Perspective
Key Companies to Watch
Executive Summary—Three Big Predictions

2. MARKET OVERVIEW

Market Segmentation
Segmentation by Tiers of Competition

3. COMPETITIVE PLAYBOOK

New Market Opportunities
Key Merger, Acquisition, and Partnership Assessment

4. DRIVERS AND RESTRAINTS—TOTAL PHARMACEUTICAL INDUSTRY IN GHANA AND NIGERIA

Market Drivers
Drivers Explained
Market Restraints
Restraints Explained
Market Impact of Key Drivers and Restraints

5. FORECASTS AND TRENDS—TOTAL PHARMACEUTICAL INDUSTRY IN GHANA AND NIGERIA

Market Engineering Measurements
Forecast Assumptions and Definitions
Revenue Forecast
Revenue Forecast Discussion
Per Cent Revenue Forecast by Region
Revenue Forecast by Region
Ghana and Nigeria—Therapeutic Segment Growth Analysis
Procurement Process

6. GHANAIAN PHARMACEUTICAL INDUSTRY OVERVIEW

Ghanaian Pharmaceutical Industry Overview
Ghana—Health Profile
Ghana—Malaria
Ghana—Tuberculosis (TB)/HIV
Ghana—Non-communicable Diseases (NCDs)

7. GHANAIAN PHARMACEUTICAL INDUSTRY—FORECASTS AND TRENDS

Ghanaian Pharmaceutical Industry
Ghanaian Pharmaceutical Industry—Market Engineering Measurements
Ghanaian Pharmaceutical Industry—Revenue Forecast
Ghanaian Pharmaceutical Industry—Revenue Forecast Discussion
Ghana—Per Cent Revenue Forecast by Product Segment
Ghana—Per Cent Revenue Forecast by Therapeutic Segment
OTC Pharmaceuticals Segment—Revenue Forecast
OTC Pharmaceuticals Segment—Revenue Forecast Discussion
Generic Pharmaceuticals Segment—Revenue Forecast
Generic Pharmaceuticals Segment—Revenue Forecast Discussion
Branded Pharmaceuticals Segment—Revenue Forecast
Branded Pharmaceuticals Segment—Revenue Forecast Discussion
Anti-infectives Segment—Revenue Forecast
Anti-infectives Segment—Revenue Forecast Discussion
Cardiovascular Segment—Revenue Forecast
Cardiovascular Segment—Revenue Forecast Discussion
Diabetes Segment—Revenue Forecast
Diabetes Segment—Revenue Forecast Discussion
Respiratory Segment—Revenue Forecast
Respiratory Segment—Revenue Forecast Discussion
CNS Segment—Revenue Forecast
CNS Segment—Revenue Forecast Discussion
Oncology Segment—Revenue Forecast
Oncology Segment—Revenue Forecast Discussion
Pricing Analysis
Ghanaian Pharmaceutical Industry—SWOT Analysis
PESTLE Analysis
Regulatory Analysis

8. GHANAIAN PHARMACEUTICAL INDUSTRY—DEMAND ANALYSIS

Ghanaian Pharmaceutical Industry—Procurement and Supply Management
Ghanaian Pharmaceutical Industry—Distribution
Ghanaian Pharmaceutical Industry—Retail
Ghanaian Pharmaceutical Industry—Demand Analysis

9. GHANAIAN PHARMACEUTICAL INDUSTRY—COMPETITIVE LANDSCAPE

Competitive Environment
Ghanaian Pharmaceutical Industry—Competitor AnalysisMultinationals
Ghanaian Pharmaceutical Industry—Competitor AnalysisGeneric Companies
Ghanaian Pharmaceutical Industry—Competitor AnalysisLocal Manufacturers
Ghanaian Pharmaceutical Industry—Competitor ProfileErnest Chemists Limited
Ghanaian Pharmaceutical Industry—Competitor ProfileKinapharma Limited
Ghanaian Pharmaceutical Industry—Competitor ProfilePhyto-Riker (GIHOC) Pharmaceutical Limited
Ghanaian Pharmaceutical Industry—Competitor ProfileAyrton Drugs Manufacturing Company Limited
Ghanaian Pharmaceutical Industry—Competitor ProfileKama Group Limited

10. NIGERIAN PHARMACEUTICAL INDUSTRY OVERVIEW

Nigerian Pharmaceutical Industry Overview
Nigeria—Health Profile
Nigeria—Malaria
Nigeria—Tuberculosis (TB)/HIV
Nigeria—Non-communicable Diseases (NCDs)

11. NIGERIAN PHARMACEUTICAL INDUSTRY—FORECASTS AND TRENDS

Nigerian Pharmaceutical Industry
Nigerian Pharmaceutical Industry—Market Engineering Measurements
Nigerian Pharmaceutical Industry—Revenue Forecast
Nigerian Pharmaceutical Industry—Revenue Forecast Discussion
Nigeria—Per Cent Revenue Forecast by Product Segment
Nigeria—Per Cent Revenue Forecast by Product and Therapeutic Segment
OTC Pharmaceuticals Segment—Revenue Forecast
OTC Pharmaceuticals Segment—Revenue Forecast Discussion
Generic Pharmaceuticals Segment—Revenue Forecast
Generic Pharmaceuticals Segment—Revenue Forecast Discussion
Branded Pharmaceuticals Segment—Revenue Forecast
Branded Pharmaceuticals Segment—Revenue Forecast Discussion
Anti-infectives Segment—Revenue Forecast
Anti-infectives Segment—Revenue Forecast Discussion
Cardiovascular Segment—Revenue Forecast
Cardiovascular Segment—Revenue Forecast Discussion
Diabetes Segment—Revenue Forecast
Diabetes Segment—Revenue Forecast Discussion
Respiratory Segment—Revenue Forecast
Respiratory Segment—Revenue Forecast Discussion
CNS Segment—Revenue Forecast
CNS Segment—Revenue Forecast Discussion
Oncology Segment—Revenue Forecast
Oncology Segment—Revenue Forecast Discussion
Pricing Analysis
Nigerian Pharmaceutical Industry—SWOT Analysis
PESTLE Analysis
Regulatory Analysis

12. NIGERIAN PHARMACEUTICAL INDUSTRY—DEMAND ANALYSIS

Nigerian Pharmaceutical Industry—Procurement and Supply Management
Nigerian Pharmaceutical Industry—Distribution
Nigerian Pharmaceutical Industry—Demand Analysis

13. NIGERIAN PHARMACEUTICAL INDUSTRY—COMPETITIVE LANDSCAPE

Competitive Environment
Nigerian Pharmaceutical Industry—Competitor AnalysisMultinationals
Nigerian Pharmaceutical Industry—Competitor AnalysisGeneric Companies
Nigerian Pharmaceutical Industry—Competitor AnalysisLocal Manufacturers
Nigerian Pharmaceutical Industry—Competitor ProfileEmzor Pharmaceutical Industries Limited
Nigerian Pharmaceutical Industry—Competitor ProfileFidson Healthcare PLC
Nigerian Pharmaceutical Industry—Competitor ProfileMay and Baker Nigeria PLC
Nigerian Pharmaceutical Industry—Competitor ProfileEvans Medical PLC
Nigerian Pharmaceutical Industry—Competitor ProfileNigeria German Chemicals PLC

14. KEY COMPANIES TO WATCH

Key Companies to Watch

15. THE LAST WORD

The Last Word—Three Big Predictions
The Last Word—Discussion
Legal Disclaimer

16. APPENDIX

Market Background
Important Market Metrics
Market Landscape and Pricing
Decision Support Database—Total Healthcare Expenditure
Decision Support Database—Public Healthcare Expenditure
Decision Support Database—Private Healthcare Expenditure
Other Related Research Services
List of Other Key Companies Included in this Research Service
Market Engineering Methodology
Learn More—Next Steps

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.